Published in J Virol on January 01, 1999
HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A (2000) 11.51
Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol (2001) 7.37
HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med (2000) 5.79
Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med (2001) 4.42
Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A (2000) 3.66
Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol (1999) 3.22
Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol (2001) 2.93
Inefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivo. PLoS Biol (2006) 2.81
Putative immunodominant human immunodeficiency virus-specific CD8(+) T-cell responses cannot be predicted by major histocompatibility complex class I haplotype. J Virol (2000) 2.51
HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest (1999) 2.42
Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection. J Clin Invest (1999) 2.00
Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A (2001) 1.89
Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J Clin Invest (2001) 1.85
Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2000) 1.73
Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci U S A (2008) 1.72
Trafficking of human immunodeficiency virus type 1-specific CD8+ T cells to gut-associated lymphoid tissue during chronic infection. J Virol (2003) 1.71
Multifunctional human immunodeficiency virus (HIV) gag-specific CD8+ T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection. J Virol (2007) 1.67
Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. J Virol (2001) 1.65
Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression. J Virol (1999) 1.63
Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection. Blood (2012) 1.60
Dynamics of immune escape during HIV/SIV infection. PLoS Comput Biol (2008) 1.54
Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol (2005) 1.54
Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection. J Clin Invest (2002) 1.50
High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. J Virol (2011) 1.44
Parallel human immunodeficiency virus type 1-specific CD8+ T-lymphocyte responses in blood and mucosa during chronic infection. J Virol (2005) 1.41
Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency. J Virol (2000) 1.38
Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3zeta and CD28, key signaling molecules for T-cell activation. J Virol (2000) 1.38
Different effects of Nef-mediated HLA class I down-regulation on human immunodeficiency virus type 1-specific CD8(+) T-cell cytolytic activity and cytokine production. J Virol (2002) 1.31
Limited sequence evolution within persistently targeted CD8 epitopes in chronic human immunodeficiency virus type 1 infection. J Virol (2005) 1.29
Population analysis of antiviral T cell responses using MHC class I-peptide tetramers. Clin Exp Immunol (2003) 1.25
Magnitude and complexity of rectal mucosa HIV-1-specific CD8+ T-cell responses during chronic infection reflect clinical status. PLoS One (2008) 1.21
Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. J Virol (2002) 1.20
Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir. AIDS (2011) 1.20
Infection of the CD45RA+ (naive) subset of peripheral CD8+ lymphocytes by human immunodeficiency virus type 1 in vivo. J Virol (2001) 1.16
Memory CD8+ T cells in HIV infection. Philos Trans R Soc Lond B Biol Sci (2000) 1.15
HIV-1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing? Proc Biol Sci (2000) 1.15
In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. PLoS Pathog (2012) 1.14
The role of antigenic stimulation and cytotoxic T cell activity in regulating the long-term immunopathogenesis of HIV: mechanisms and clinical implications. Proc Biol Sci (2001) 1.14
Small variations in multiple parameters account for wide variations in HIV-1 set-points: a novel modelling approach. Proc Biol Sci (2001) 1.08
Expansion and contraction of HIV-specific CD4 T cells with short bursts of viremia, but physical loss of the majority of these cells with sustained viral replication. J Immunol (2005) 1.08
Immune activation and collateral damage in AIDS pathogenesis. Front Immunol (2013) 1.08
Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection. Blood (2012) 1.03
Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus. J Virol (2004) 1.01
Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals. J Virol (2001) 1.01
Characterizing the immune system after long-term undetectable viral load in HIV-1-infected children. J Clin Immunol (2003) 0.98
Clonotype and repertoire changes drive the functional improvement of HIV-specific CD8 T cell populations under conditions of limited antigenic stimulation. J Immunol (2011) 0.98
Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection. J Virol (2002) 0.97
CD8 T cell persistence in treated HIV infection. Curr Opin HIV AIDS (2014) 0.97
Quantification of intrinsic residual viral replication in treated HIV-infected patients. Proc Natl Acad Sci U S A (2001) 0.95
Immunity to HIV-1 is influenced by continued natural exposure to exogenous virus. PLoS Pathog (2008) 0.95
Two types of cytotoxic lymphocyte regulation explain kinetics of immune response to human immunodeficiency virus. Proc Natl Acad Sci U S A (2006) 0.94
Decreases in plasma TNF-alpha level and IFN-gamma mRNA level in peripheral blood mononuclear cells (PBMC) and an increase in IL-2 mRNA level in PBMC are associated with effective highly active antiretroviral therapy in HIV-infected patients. Clin Exp Immunol (2003) 0.93
The role of recombination for the coevolutionary dynamics of HIV and the immune response. PLoS One (2011) 0.92
Impact of highly active antiretroviral therapy initiation on CD4(+) T-cell repopulation in duodenal and rectal mucosa. AIDS (2013) 0.91
Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells. J Virol (2001) 0.90
Optimal HIV treatment by maximising immune response. J Math Biol (2003) 0.89
Persistence of genital tract T cell responses in HIV-infected women on highly active antiretroviral therapy. J Virol (2010) 0.88
Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy. Sex Transm Infect (1999) 0.87
Immunologic pressure within class I-restricted cognate human immunodeficiency virus epitopes during highly active antiretroviral therapy. J Virol (2005) 0.87
Antiretroviral therapy reduces the magnitude and T cell receptor repertoire diversity of HIV-specific T cell responses without changing T cell clonotype dominance. J Virol (2012) 0.87
Finding Balance: T cell Regulatory Receptor Expression during Aging. Aging Dis (2011) 0.86
HIV versus the immune system: another apparent victory for the virus. J Clin Invest (2001) 0.86
Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine. Vaccine (2012) 0.86
HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses. J Virol (2015) 0.86
HIV-specific CD8+ T cells and HIV eradication. J Clin Invest (2016) 0.85
Elevation and persistence of CD8 T-cells in HIV infection: the Achilles heel in the ART era. J Int AIDS Soc (2016) 0.85
Large HIV-specific CD8 cytotoxic T-lymphocyte (CTL) clones reduce their overall size but maintain high frequencies of memory CTL following highly active antiretroviral therapy. Immunology (2006) 0.83
Model with two types of CTL regulation and experiments on CTL dynamics. J Theor Biol (2009) 0.83
HIV therapy: managing resistance. Proc Natl Acad Sci U S A (2000) 0.82
Mesenchymal stem cell derived hematopoietic cells are permissive to HIV-1 infection. Retrovirology (2011) 0.82
Immune escape mutations detected within HIV-1 epitopes associated with viral control during treatment interruption. J Acquir Immune Defic Syndr (2010) 0.81
Do HIV-specific CTL continue to have an antiviral function during antiretroviral therapy? If not, why not, and what can be done about it? Front Immunol (2013) 0.80
Preserving HIV-specific T cell responses: does timing of antiretroviral therapy help? Curr Opin HIV AIDS (2015) 0.80
A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability. PLoS Comput Biol (2012) 0.80
Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune responses. Proc Biol Sci (2010) 0.79
Predicting the impact of blocking human immunodeficiency virus type 1 Nef in vivo. J Virol (2008) 0.79
The route of HIV escape from immune response targeting multiple sites is determined by the cost-benefit tradeoff of escape mutations. PLoS Comput Biol (2014) 0.79
Immunological effects of interleukin-2 therapy in human immunodeficiency virus-positive subjects. Clin Diagn Lab Immunol (2001) 0.79
High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia. AIDS (2012) 0.79
Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort. BMC Infect Dis (2013) 0.78
Biologically-directed modeling reflects cytolytic clearance of SIV-infected cells in vivo in macaques. PLoS One (2012) 0.78
The challenge of immune control of immunodeficiency virus. J Clin Invest (1999) 0.78
Decay kinetics of HIV-1 specific T cell responses in vertically HIV-1 exposed seronegative infants. Front Immunol (2012) 0.77
Longitudinal changes in HIV-specific IFN-gamma secretion in subjects who received Remune vaccination prior to treatment interruption. J Immune Based Ther Vaccines (2006) 0.77
The role of the cytotoxic T-lymphocyte response and virus cytopathogenicity in the virus decline during antiviral therapy. Proc Biol Sci (2003) 0.77
Viral and Cellular Dynamics in HIV Disease. Curr Infect Dis Rep (2001) 0.77
Notwithstanding Circumstantial Alibis, Cytotoxic T Cells Can Be Major Killers of HIV-1-Infected Cells. J Virol (2016) 0.77
Single-dose nevirapine exposure affects T cell response and cytokine levels in HIV type 1-infected women. AIDS Res Hum Retroviruses (2009) 0.77
Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170). AIDS (2012) 0.77
MHC class II genotype and the control of viremia in HIV-1-infected individuals on highly active antiretroviral therapy. J Clin Invest (2001) 0.76
Interpreting the effect of vaccination on steady state infection in animals challenged with Simian immunodeficiency virus. J Theor Biol (2009) 0.76
The immune response to the RT181-189 epitope in HIV-1-infected patients is associated with viral sequence polymorphism flanking the epitope. J Clin Immunol (2011) 0.76
Supranormal thymic output up to 2 decades after HIV-1 infection. AIDS (2016) 0.76
Effects of neutralizing antibodies on escape from CD8+ T-cell responses in HIV-1 infection. Philos Trans R Soc Lond B Biol Sci (2015) 0.76
Nevirapine inhibits the anti-HIV activity of CD8+ cells. J Acquir Immune Defic Syndr (2013) 0.75
Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity (1998) 17.27
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 15.09
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 12.05
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science (1997) 10.35
Immunological memory and protective immunity: understanding their relation. Science (1996) 10.02
Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 5.30
T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. Clin Immunol Immunopathol (1989) 3.00
High frequency of memory and effector gag specific cytotoxic T lymphocytes in HIV seropositive individuals. Int Immunol (1990) 2.71
Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis (1996) 2.44
Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J Immunol (1992) 2.32
Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors. Proc Natl Acad Sci U S A (1995) 2.30
Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J Theor Biol (1997) 2.30
An optimal viral peptide recognized by CD8+ T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. Proc Natl Acad Sci U S A (1991) 2.26
CD8+ lymphocyte responses to antiretroviral therapy of HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 2.23
Oligoclonal expansions of CD8(+) T cells in chronic HIV infection are antigen specific. J Exp Med (1998) 2.13
Toward HIV eradication or remission: the tasks ahead. Science (1998) 1.88
Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1. J Virol (1999) 1.63
A functional and kinetic comparison of antiviral effector and memory cytotoxic T lymphocyte populations in vivo and in vitro. Eur J Immunol (1997) 1.52
The CD38 lymphocyte differentiation marker: new insight into its ectoenzymatic activity and its role as a signal transducer. Immunity (1997) 1.35
Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa. J Virol (1999) 1.20
Identification of multiple HIV-1 cytotoxic T-cell epitopes presented by human leukocyte antigen B35 molecules. AIDS (1996) 1.16
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
Viral dynamics in human immunodeficiency virus type 1 infection. Nature (1995) 28.54
Phenotypic analysis of antigen-specific T lymphocytes. Science (1996) 24.26
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell (1986) 14.96
Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med (1999) 14.30
Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science (1993) 13.87
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 13.76
Decay characteristics of HIV-1-infected compartments during combination therapy. Nature (1997) 13.68
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med (1997) 12.26
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 12.05
Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature (1991) 10.85
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med (1996) 10.62
Common west African HLA antigens are associated with protection from severe malaria. Nature (1991) 9.43
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62
Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol (1993) 8.62
Cytotoxic T-cell immunity to influenza. N Engl J Med (1983) 8.49
mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. Cell (1999) 8.38
Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med (1995) 8.23
Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell (2001) 8.04
Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature (2001) 7.90
Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med (1991) 7.83
Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science (1996) 7.73
Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science (2001) 7.66
Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol (2001) 7.37
Bias due to misclassification in the estimation of relative risk. Am J Epidemiol (1977) 7.28
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature (1998) 7.12
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med (1999) 7.07
Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med (1985) 6.54
Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med (2001) 6.51
High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A (1990) 6.49
Standardized mortality ratios and the "healthy worker effect": Scratching beneath the surface. J Occup Med (1976) 6.40
Rapid effector function in CD8+ memory T cells. J Exp Med (1997) 6.36
Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol (1995) 6.33
Adaptive evolution of highly mutable loci in pathogenic bacteria. Curr Biol (1994) 6.17
Analysis of gene expression in single live neurons. Proc Natl Acad Sci U S A (1992) 6.15
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med (1996) 6.14
Cooperation and competition in the evolution of ATP-producing pathways. Science (2001) 6.04
Infection of monocyte/macrophages by human T lymphotropic virus type III. J Clin Invest (1986) 5.90
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med (2000) 5.79
Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med (1996) 5.63
Environmental exposure to lead and children's intelligence at the age of seven years. The Port Pirie Cohort Study. N Engl J Med (1992) 5.49
HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature (1988) 5.45
Differential functions of mPer1, mPer2, and mPer3 in the SCN circadian clock. Neuron (2001) 5.36
Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med (1996) 5.35
Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med (1998) 5.33
A human thymocyte antigen defined by a hybrid myeloma monoclonal antibody. Eur J Immunol (1979) 5.17
Genome sequence of the plant pathogen and biotechnology agent Agrobacterium tumefaciens C58. Science (2001) 5.16
Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol (1987) 5.03
Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol (1993) 4.83
An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell (2001) 4.79
Cellular immune responses to HIV. Nature (2001) 4.61
HTLV-III in the semen and blood of a healthy homosexual man. Science (1984) 4.53
Declining blood lead levels and cognitive changes in moderately lead-poisoned children. JAMA (1993) 4.46
The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol (1996) 4.45
Potential impact of global climate change on malaria risk. Environ Health Perspect (1995) 4.44
A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml. Nucleic Acids Res (1997) 4.40
Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet (1999) 4.36
Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J (1986) 4.32
Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A (2000) 4.22
Reward and punishment. Proc Natl Acad Sci U S A (2001) 4.10
The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med (2000) 4.08